Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

And although shares fell 35% from peak-to-trough, it became apparent that those who seek these weight-loss drugs also tend to ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

ResMed Inc. (RMD)股价创下了显著的里程碑，飙升至52周新高260.71美元。根据 InvestingPro 分析，这家市值382亿美元的医疗设备巨头保持着强劲的财务健康状况。这一峰值反映了该医疗设备公司的显著上升趋势，其股价在过去一年中增长了36.7%。公司的稳健表现得到了9.9%的稳定收入增长和连续13年的稳定派息历史的支持。投资者和市场分析师正密切关注ResMed的表现，因为该 ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Citi analyst Mathieu Chevrier raised the firm’s price target on ResMed (RMD) to A$41 from A$38 and keeps a Neutral rating on the shares ...

The decline in stock value comes as analysts express mixed views on the company's quarterly performance. While ResMed achieved a 10% revenue increase compared to the same quarter last year, some ...

We award ResMed a narrow moat rating based on switching costs and intangible assets, which have helped the company achieve high customer adherence rates and above-average industry growth.

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...